Collectively, these findings suggest that cFLIPL and cFLIPS play opposing regulatory roles in modulating NF-κB signaling and IL-8 expression downstream of TRAIL-R2/DR5 activation in glutamine-starved colon cancer cells. Here, CFLAR is linked to malignant colon neoplasm.